Additional information:
GRL0617 is a potent, selective and competitive noncovalent inhibitor of SARS PLPro. GRL0617, inhibited SARS-CoV viral replication in Vero E6 cells with an EC(50) of 15 microM and had no associated cytotoxicity. The X-ray structure of PLpro in complex with GRL0617 indicates that the compound has a unique mode of inhibition whereby it binds within the S4-S3 subsites of the enzyme and induces a loop closure that shuts down catalysis at the active site.{{Emtricitabine} MedChemExpress|{Emtricitabine} Endogenous Metabolite|{Emtricitabine} Protocol|{Emtricitabine} Formula|{Emtricitabine} supplier|{Emtricitabine} Epigenetic Reader Domain} |Product information|CAS Number: 1093070-16-6|Molecular Weight: 304.{{Capsaicin} medchemexpress|{Capsaicin} Apoptosis|{Capsaicin} Biological Activity|{Capsaicin} In Vitro|{Capsaicin} supplier|{Capsaicin} Autophagy} 39|Formula: C20H20N2O|Synonym:|GRL-0617|GRL0617|GRL 0617|Chemical Name: 5-Amino-2-methyl-N-[(1R)-1-(1-naphthalenyl)ethyl]benzamide|Smiles: CC1=CC=C(N)C=C1C(=O)N[C@H](C)C1=CC=CC2=CC=CC=C21|InChiKey: UVERBUNNCOKGNZ-CQSZACIVSA-N|InChi: InChI=1S/C20H20N2O/c1-13-10-11-16(21)12-19(13)20(23)22-14(2)17-9-5-7-15-6-3-4-8-18(15)17/h3-12,14H,21H2,1-2H3,(H,22,23)/t14-/m1/s1|Technical Data|Appearance: Solid Power.PMID:35126464 |Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined.|HS Tariff Code: 382200|References:|Chaudhuri R, Tang S, Zhao G, Lu H, Case DA, Johnson ME. Comparison of SARS and NL63 papain-like protease binding sites and binding site dynamics: inhibitor design implications. J Mol Biol. 2011 Nov 25;414(2):272-88. doi: 10.1016/j.jmb.2011.09.030. Epub 2011 Sep 29. PubMed PMID: 22004941; PubMed Central PMCID: PMC3397151.Nathan J. SchauerRobert S. MaginXiaoxi LiuLaura M. DohertySara J. Buhrlage* Advances in Discovering Deubiquitinating Enzyme (DUB) Inhibitors. Journal of Medicinal Chemistry, Articles ASAP (Perspective). Publication Date (Web):November 4, 2019DOI: 10.1021/acs.jmedchem.9b01138.Products are for research use only. Not for human use.|

Additional information:
VUN65671is a Potent Entry Inhibitor of Ebola and Marburg Virus Infections. VUN65671 was reported in Journal of Medicinal Chemistry (2020), 63(13), 7211-7225.|Product information|CAS Number: 2479465-67-1|Molecular Weight: 461.52|Formula: C25H30F3N3O2|Synonym:|VUN-65671|VUN65671|VUN 65671|Chemical Name: Benzamide,N-[4-(4-methyl-1-piperidinyl)-3-(trifluoromethyl)phenyl]-4-(4-morpholinylmethyl)-|Smiles: CC1CCN(CC1)C1=CC=C(C=C1C(F)(F)F)NC(=O)C1C=CC(CN2CCOCC2)=CC=1|InChiKey: VVJSZYWIEBDKTC-UHFFFAOYSA-N|InChi: InChI=1S/C25H30F3N3O2/c1-18-8-10-31(11-9-18)23-7-6-21(16-22(23)25(26,27)28)29-24(32)20-4-2-19(3-5-20)17-30-12-14-33-15-13-30/h2-7,16,18H,8-15,17H2,1H3,(H,29,32)|Technical Data|Appearance: Solid Power.|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Lanreotide} web|{Lanreotide} Biological Activity|{Lanreotide} Purity|{Lanreotide} supplier|{Lanreotide} Epigenetics} |Shelf Life: ≥360 days if stored properly.{{Sirukumab} site|{Sirukumab} Interleukin Related|{Sirukumab} Protocol|{Sirukumab} In Vivo|{Sirukumab} custom synthesis|{Sirukumab} Autophagy} |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:23514335 |Drug Formulation: To be determined.|HS Tariff Code: 382200|How to use|In Vitro:|EBOV/MARV-IN-1 (12.5 µM; 48 h) inhibits HIV/EBOV-GP (EC50=12 nM) and HIV/MARV-GP (EC50=180 nM) pseudotype virus in A549 cells containing a luciferase reporter gene, with low cytotoxicity (SI =2088).|References:|Gaisina IN, et, al. Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections. J Med Chem. 2020 Jul 9;63(13):7211-7225.Products are for research use only. Not for human use.|

Additional information:
YC-1 is a inhibitor of Hypoxia-inducible factor-1alpha (HIF-1alpha). YC-1 is widely used as a potent inhibitor of HIF-1alpha both in vitro and in vivo, and is also being developed as a novel anticancer drug. YC-1 effectively inhibits tumor invasion and metastasis, and imply that YC-1 is worth while to further develop as a multipurpose anticancer drug.|Product information|CAS Number: 170632-47-0|Molecular Weight: 304.34|Formula: C19H16N2O2|Synonym:|Lificiguat|YC1|YC 1|YC-1|Chemical Name: 5-[1-(phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol|Smiles: OCC1=CC=C(O1)C1=NN(CC2C=CC=CC=2)C2=CC=CC=C21|InChiKey: OQQVFCKUDYMWGV-UHFFFAOYSA-N|InChi: InChI=1S/C19H16N2O2/c22-13-15-10-11-18(23-15)19-16-8-4-5-9-17(16)21(20-19)12-14-6-2-1-3-7-14/h1-11,22H,12-13H2|Technical Data|Appearance: Solid Power.PMID:24463635 |Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO, not in water|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined.|HS Tariff Code: 382200|References:|Tsui L, Fong TH, Wang IJ. The effect of 3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole (YC-1) on cell viability under hypoxia. Mol Vis. 2013 Nov 16;19:2260-73. eCollection 2013. PubMed PMID: 24265542; PubMed Central PMCID: PMC3834593.Carroll CE, Liang Y, Benakanakere I, Besch-Williford C, Hyder SM. The anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor development. Int J Oncol. 2013 Jan;42(1):179-87. doi: 10.3892/ijo.2012.1675. Epub 2012 Oct 24. PubMed PMID: 23123638; PubMed Central PMCID: PMC3583650.Tsui L, Fong TH, Wang IJ. YC-1 targeting of hypoxia-inducible factor-1α reduces RGC-5 cell viability and inhibits cell proliferation. Mol Vis. 2012;18:1594-603. Epub 2012 Jun 15. PubMed PMID: 22736948; PubMed Central PMCID: PMC3380911.Products are for research use only. Not for human use.|

Additional information:
Ciraparantag (free base), also known as PER977, is a small molecule reversal agent for new oral anticoagulants and heparins. PER977 is a water-soluble, cationic molecule that is designed to bind specifically to unfractionated heparin and low-molecular-weight heparin through noncovalent hydrogen bonding and charge–charge interactions.|Product information|CAS Number: 1438492-26-2|Molecular Weight: 512.70|Formula: C22H48N12O2|Synonym:|PER977|PER-977|PER 977|Aripazine|Ciraparantag|Chemical Name: (2S,2’S)-N,N’-(piperazine-1,4-diylbis(propane-3,1-diyl))bis(2-amino-5-guanidinopentanamide)|Smiles: NC(=N)NCCC[C@H](N)C(=O)NCCCN1CCN(CC1)CCCNC(=O)[C@@H](N)CCCNC(N)=N|InChiKey: HRDUUSCYRPOMSO-ROUUACIJSA-N|InChi: InChI=1S/C22H48N12O2/c23-17(5-1-7-31-21(25)26)19(35)29-9-3-11-33-13-15-34(16-14-33)12-4-10-30-20(36)18(24)6-2-8-32-22(27)28/h17-18H,1-16,23-24H2,(H,29,35)(H,30,36)(H4,25,26,31)(H4,27,28,32)/t17-,18-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO, not in water|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined.|HS Tariff Code: 382200|References:|Dzik WH. Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re-appraisal. J Thromb Haemost. 2015 Jun;13 Suppl 1:S187-94. doi: 10.1111/jth.12949. PubMed PMID: 26149022.Crowther M, Crowther MA. Antidotes for Novel Oral Anticoagulants: Current Status and Future Potential.{{Nimodipine} MedChemExpress|{Nimodipine} Membrane Transporter/Ion Channel|{Nimodipine} Purity & Documentation|{Nimodipine} Data Sheet|{Nimodipine} supplier|{Nimodipine} Cancer} Arterioscler Thromb Vasc Biol.{{Biotin-PEG4-NHS ester} web|{Biotin-PEG4-NHS ester} PROTAC Linkers|{Biotin-PEG4-NHS ester} TGF-beta/Smad|{Biotin-PEG4-NHS ester} Technical Information|{Biotin-PEG4-NHS ester} References|{Biotin-PEG4-NHS ester} custom synthesis} 2015 Aug;35(8):1736-45.PMID:28739548 doi: 10.1161/ATVBAHA.114.303402. Epub 2015 Jun 18. PubMed PMID: 26088576.Sullivan DW Jr, Gad SC, Laulicht B, Bakhru S, Steiner S. Nonclinical Safety Assessment of PER977: A Small Molecule Reversal Agent for New Oral Anticoagulants and Heparins. Int J Toxicol. 2015 Jun 15. pii: 1091581815590667. [Epub ahead of print] PubMed PMID: 26079256.Mo Y, Yam FK. Recent advances in the development of specific antidotes for target-specific oral anticoagulants. Pharmacotherapy. 2015 Feb;35(2):198-207. doi: 10.1002/phar.1532. Epub 2015 Feb 3. PubMed PMID: 25644580.Yates SW. Interrupting anticoagulation in patients with nonvalvular atrial fibrillation. P T. 2014 Dec;39(12):858-80. PubMed PMID: 25516695; PubMed Central PMCID: PMC4264672.Products are for research use only. Not for human use.|

Additional information:
CB-5083 is a novel first in class, potent orally bio-available p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models . CB-5083 causes rapid and sustained accumulation of poly-ubiquitin in tumor xenografts after a single administration. CB-5083 showed activity to inhibit tumor growth in multiple rodent models of human cancer. Furthermore, CB-5083 appears to exhibit greater potency over current proteasome inhibitors that further validate targeting p97 and protein homeostasis in the treatment of cancer.|Product information|CAS Number: 1542705-92-9|Molecular Weight: 413.47|Formula: C24H23N5O2|Chemical Name: 1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide|Smiles: CC1=CC2C(=CC=CC=2C(N)=O)N1C1=NC2CCOCC=2C(NCC2C=CC=CC=2)=N1|InChiKey: RDALZZCKQFLGJP-UHFFFAOYSA-N|InChi: InChI=1S/C24H23N5O2/c1-15-12-18-17(22(25)30)8-5-9-21(18)29(15)24-27-20-10-11-31-14-19(20)23(28-24)26-13-16-6-3-2-4-7-16/h2-9,12H,10-11,13-14H2,1H3,(H2,25,30)(H,26,27,28)|Technical Data|Appearance: Solid Power.{{Carbamazepine} web|{Carbamazepine} Sodium Channel|{Carbamazepine} Technical Information|{Carbamazepine} In Vitro|{Carbamazepine} manufacturer|{Carbamazepine} Cancer} |Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO up to 100 mM|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Biotin-PEG4-NHS ester} web|{Biotin-PEG4-NHS ester} PROTAC Linkers|{Biotin-PEG4-NHS ester} Epigenetics|{Biotin-PEG4-NHS ester} Protocol|{Biotin-PEG4-NHS ester} References|{Biotin-PEG4-NHS ester} supplier} |Shelf Life: ≥12 months if stored properly.PMID:24914310 |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined.|HS Tariff Code: 382200|How to use|In Vitro:|CB-5083 was used at 1-2.5 µM final concentration in various assays.|In Vivo:|CB-5083 was dosed to mice orally at 25-100 mg/Kg once or twice per day.|References:|Zhou HJ, et al. Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083). (2015) J Med Chem. 58(24):9480-97.Products are for research use only. Not for human use.|Documents||

Additional information:
AR7 was developed as a highly potent and selective enhancer of the chaperone-mediated autophagy (CMA) through antagonizing RARα.PMID:24268253 It is a synthetic derivative of all-trans-retinoic acid developed through the structure-based chemical design. CMA contributes to cellular quality control and the cellular response to stress through the selective degradation of cytosolic proteins in lysosomes. A decrease in CMA activity occurs in aging and in age-related disorders (such as neurodegenerative diseases and diabetes). AR7 is the first small molecule developed to selectively stimulate CMA without affecting macroautophagy. Importantly, AR7 was shown to protect cells from oxidative stress and proteotoxicity, presenting a potential therapeutic strategy against cellular dysfunction and disease resulted from reduced CMA.|Product information|CAS Number: 80306-38-3|Molecular Weight: 257.71|Formula: C15H12ClNO|Synonym:|AR-7|AR 7|AR7|Atypical retinoid 7|Chemical Name: 7-chloro-3-(p-tolyl)-2H-benzo[b][1,4]oxazine|Smiles: CC1C=CC(=CC=1)C1COC2=CC(Cl)=CC=C2N=1|InChiKey: MVOZLTFXYGHZPM-UHFFFAOYSA-N|InChi: InChI=1S/C15H12ClNO/c1-10-2-4-11(5-3-10)14-9-18-15-8-12(16)6-7-13(15)17-14/h2-8H,9H2,1H3|Technical Data|Appearance: Solid Power.|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO up to 100 mM|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined.|HS Tariff Code: 382200|How to use|In Vitro:|AR7 was suggested to be used at 5-20 µM final concentration in vitro and in cellular assays.|References:|Anguiano J, et al. Chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives. (2013) Nat Chem Biol. 9(6):374-82.Products are for research use only. Not for human use.|

Additional information:
LY2109761 is a highly potent and selective TGFβ receptor type I and type II (TβRI/II) inhibitor with Ki of 38 nM and 300 nM respectively.PMID:23910527 Blocking TβRI/II kinase activity with LY2109761 completely suppresses both the basal and TGF-β1-stimulated migration and invasion of L3.6pl/GLT cells, and completely suppresses TGF-β–induced Smad2 phosphorylation. LY2109761 treatment at 1 nM is sufficient to significantly block the migration and invasion but not adhesion of hepatocellular carcinoma cells by increasing E-cadherin expression. It can also reduce the self-renewal and proliferation of GBM-derived cancer stem–like cells, which can be significantly enhanced when combined with radiation. Administration of LY2109761 alone or in combination with gemcitabine or with radiation demonstrated very good efficacy in multiple xenograft mice models.|Product information|CAS Number: 700874-71-1|Molecular Weight: 441.52|Formula: C26H27N5O2|Synonym:|LY 2109761|LY-2109761|Chemical Name: 4-(2-((4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl)oxy)ethyl)morpholine|Smiles: C(COC1=CC2=NC=CC(C3C(=NN4CCCC4=3)C3=CC=CC=N3)=C2C=C1)N1CCOCC1|InChiKey: IHLVSLOZUHKNMQ-UHFFFAOYSA-N|InChi: InChI=1S/C26H27N5O2/c1-2-9-27-22(4-1)26-25(24-5-3-11-31(24)29-26)21-8-10-28-23-18-19(6-7-20(21)23)33-17-14-30-12-15-32-16-13-30/h1-2,4,6-10,18H,3,5,11-17H2|Technical Data|Appearance: Solid Power.|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO up to 100 mM|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined.|HS Tariff Code: 382200|How to use|In Vitro:|LY2109761 was usually used at 5-10 µM in vitro and in cellular assays.|In Vivo:|LY2109761 was orally dosed to mice at 50 mg/kg once per day or in combination with gemcitabine (25 mg/kg) to significantly reduce the tumor volume.|References:|Li HY, et al. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent. (2008) J Med Chem. 51(7):2302-6.Melisi D, et al. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. (2008) Mol Cancer Ther. 7(4):829-40.Zhang B, et al. Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. (2009) Cancer Lett. 277(1):114-20.Connolly EC, et al. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761. (2011) Cancer Res. 71(6):2339-49.Zhang M, et al. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. (2011) Cancer Res. 71(23):7155-67.Flechsig P, et al. LY2109761 Attenuates Radiation-Induced Pulmonary Murine Fibrosis via Reversal of TGF-β and BMP-Associated Proinflammatory and Proangiogenic Signals. (2012) Clin Cancer Res. 18(13):3616-27Products are for research use only. Not for human use.|Documents||

Additional information:
TNP-351 is an antifolate.{{BMP-4 Protein, Human} web|{BMP-4 Protein, Human} Technical Information|{BMP-4 Protein, Human} Description|{BMP-4 Protein, Human} custom synthesis|{BMP-4 Protein, Human} Autophagy} TNP-351, a dihydrofolate reductase (DHFR) inhibitor, has potent antitumor activity against not only leukemia cells but also solid tumor cells in vitro and in vivo.{{Gimeracil} web|{Gimeracil} Purity & Documentation|{Gimeracil} In stock|{Gimeracil} custom synthesis|{Gimeracil} Autophagy} |Product information|CAS Number: 125991-51-7|Molecular Weight: 440.45|Formula: C21H24N6O5|Chemical Name: (2S)-2-{[4-(3-{2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl}propyl)phenyl]formamido}pentanedioic acid|Smiles: NC1N=C(N)C2=C(NC=C2CCCC2C=CC(=CC=2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=1|InChiKey: WLGCEMWNUHSIIS-AWEZNQCLSA-N|InChi: InChI=1S/C21H24N6O5/c22-17-16-13(10-24-18(16)27-21(23)26-17)3-1-2-11-4-6-12(7-5-11)19(30)25-14(20(31)32)8-9-15(28)29/h4-7,10,14H,1-3,8-9H2,(H,25,30)(H,28,29)(H,31,32)(H5,22,23,24,26,27)/t14-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:24733396 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|TNP-351 inhibits the proliferation of mouse L1210 leukemia cells and human CCRF-CEM lymphoblastic leukemia cells with ED50 values of 0.79 and 2.7 nM, respectively. The ED50 values determined for the parent cell line CCRF-CEM, CCRFCEM R30/6 subline, CCRF-CEM R1, and CCRF-CEM R2 are 2.7, 5.8, 94 and 76 nM, respectively.|Products are for research use only. Not for human use.|

Additional information:
CL2 Linker is a cleavableADC linker.PMID:24733396 CL2-SN-38 and CL2A-SN-38 are equivalent in drug substitution (~6), cell binding (Kd ~1.2 nM), cytotoxicity (IC50 ~2.2 nM), and serum stability in vitro (t1/2 ~20 hours).|Product information|CAS Number: 2270986-66-6|Molecular Weight: 1426.61|Formula: C68H103N11O22|Chemical Name: tert-butyl N-[(5S)-5-[(2S)-2-[1-(4-{[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido]methyl}-1H-1,2,3-triazol-1-yl)-3,6,9,12,15,18,21,24-octaoxaheptacosan-27-amido]-3-phenylpropanamido]-5-{[4-({[(2-{[(3-hydroxy-2-oxopropoxy)carbonyl](methyl)amino}ethyl)(methyl)carbamoyl]oxy}methyl)phenyl]carbamoyl}pentyl]carbamate|Smiles: CN(CCN(C)C(=O)OCC(=O)CO)C(=O)OCC1C=CC(=CC=1)NC(=O)[C@H](CCCCNC(=O)OC(C)(C)C)NC(=O)[C@H](CC1C=CC=CC=1)NC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCN1C=C(CNC(=O)CCCCCN2C(=O)C=CC2=O)N=N1|InChiKey: BGFZCTPREVDQQQ-YQOHNZFASA-N|InChi: InChI=1S/C68H103N11O22/c1-68(2,3)101-65(88)69-25-12-11-16-57(63(86)71-54-20-18-53(19-21-54)50-99-66(89)76(4)27-28-77(5)67(90)100-51-56(81)49-80)73-64(87)58(46-52-14-8-6-9-15-52)72-60(83)24-30-91-32-34-93-36-38-95-40-42-97-44-45-98-43-41-96-39-37-94-35-33-92-31-29-78-48-55(74-75-78)47-70-59(82)17-10-7-13-26-79-61(84)22-23-62(79)85/h6,8-9,14-15,18-23,48,57-58,80H,7,10-13,16-17,24-47,49-51H2,1-5H3,(H,69,88)(H,70,82)(H,71,86)(H,72,83)(H,73,87)/t57-,58-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|Products are for research use only. Not for human use.|

Additional information:
Gardenin B is a flavonoid isolated from Baccharis scandens.{{Troriluzole} MedChemExpress|{Troriluzole} Biological Activity|{Troriluzole} In stock|{Troriluzole} manufacturer|{Troriluzole} Epigenetic Reader Domain} Gardenin B induces cell death in human leukemia cells involves multiple caspases.{{Magrolimab} medchemexpress|{Magrolimab} CD47|{Magrolimab} Protocol|{Magrolimab} Purity|{Magrolimab} supplier|{Magrolimab} Cancer} |Product information|CAS Number: 2798-20-1|Molecular Weight: 358.34|Formula: C19H18O7|Chemical Name: 5-hydroxy-6,7,8-trimethoxy-2-(4-methoxyphenyl)-4H-chromen-4-one|Smiles: COC1C=CC(=CC=1)C1=CC(=O)C2=C(O)C(OC)=C(OC)C(OC)=C2O1|InChiKey: LXEVSYZNYDZSOB-UHFFFAOYSA-N|InChi: InChI=1S/C19H18O7/c1-22-11-7-5-10(6-8-11)13-9-12(20)14-15(21)17(23-2)19(25-4)18(24-3)16(14)26-13/h5-9,21H,1-4H3|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 16.PMID:24580853 67 mg/mL (46.52 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|Products are for research use only. Not for human use.|